MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-19-2024
Renalytix AI plc Revenue 2011-2026 | RNLX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Renalytix AI plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.29 M | 3.4 M | 2.97 M | 1.49 M | -63 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.4 M | -63 K | 2.02 M |
Quarterly Revenue Renalytix AI plc
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 522 K | - | 535 K | 709 K | 459 K | - | 724 K | 1.19 M | 969 K | - | 812 K | 845 K | - | - | 619 K | 400 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.19 M | 400 K | 708 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
41 M | $ 19.02 | 0.21 % | $ 99.4 M |  Israel |
 |
Co-Diagnostics
CODX
|
6.81 M | $ 0.17 | -6.7 % | $ 4.99 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
508 M | $ 20.15 | -2.3 % | $ 217 M |  China |
 |
Danaher Corporation
DHR
|
23.9 B | $ 228.92 | -0.76 % | $ 167 B | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
3.62 B | $ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
BioNano Genomics
BNGO
|
30.8 M | $ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 38.9 | -1.04 % | $ 1.08 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
20.4 M | $ 11.38 | 6.36 % | $ 323 M | Israel |
 |
IQVIA Holdings
IQV
|
15.4 B | $ 225.41 | -1.0 % | $ 40.9 B | USA |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
2.76 B | $ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 26.27 | -0.83 % | $ 794 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
280 M | $ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
Myriad Genetics
MYGN
|
838 M | $ 6.15 | -0.32 % | $ 557 M | USA |
 |
NeoGenomics
NEO
|
661 M | $ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
National Research Corporation
NRC
|
149 M | $ 18.77 | 0.64 % | $ 461 M | USA |
 |
Anixa Biosciences
ANIX
|
210 K | $ 3.12 | - | $ 99.5 K | USA |
 |
Koninklijke Philips N.V.
PHG
|
18 B | $ 27.08 | -1.13 % | $ 20 B |  Niderland |
 |
Precipio
PRPO
|
15.2 M | $ 22.98 | -1.84 % | $ 29.8 M | USA |
 |
Personalis
PSNL
|
84.6 M | $ 7.96 | -0.13 % | $ 472 M | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
739 M | $ 102.14 | 1.53 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
 |
Soleno Therapeutics
SLNO
|
1.45 M | $ 46.3 | 0.02 % | $ 1.86 B | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
Illumina
ILMN
|
4.37 B | $ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
4.05 B | $ 199.48 | -1.24 % | $ 10.2 B | USA |
 |
Thermo Fisher Scientific
TMO
|
42.9 B | $ 579.45 | -0.69 % | $ 221 B | USA |
 |
Trinity Biotech plc
TRIB
|
61.6 M | $ 0.79 | -3.54 % | $ 61.9 M |  Irlanda |
 |
Quest Diagnostics Incorporated
DGX
|
9.87 B | $ 173.53 | -1.12 % | $ 19.3 B | USA |
|
Biodesix
BDSX
|
71.3 M | $ 6.8 | 1.19 % | $ 882 M | USA |
 |
Twist Bioscience Corporation
TWST
|
377 M | $ 31.72 | -1.34 % | $ 1.9 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
13 B | $ 250.88 | -0.87 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 182.22 | -0.43 % | $ 15 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
3.9 B | $ 676.53 | -0.85 % | $ 55.8 B | USA |